This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Inhibition of telomerase with human telomerase reverse
transcriptase antisense increases the sensitivity of tumor necrosis
factor-a-induced apoptosis in prostate cancer cells
Xiao-Dong Gao1, Yi-Rong Chen2
1Department of Urology, Lanzhou University, Lanzhou 730000, China
2Department of Urology, People's Hospital of Gansu Province, Lanzhou 730000, China
Abstract
Aim: To investigate the effect of inhibition of telomerase with human telomerase reverse transcriptase (hTERT)
antisense on tumor necrosis factor-α (TNF-α)-induced apoptosis in prostate cancer cells
(PC3). Methods: Antisense phosphorothioate oligodeoxynucleotide (AS PS-ODN) was synthesized and purified. Telomerase activity was
measured using the telomeric repeat amplification protocol (TRAP) and polymerase chain reaction enzyme-linked
immunoassay (PCR-ELISA). hTERT mRNA was measured by reverse transcription PCR (RT-PCR) assay and gel-image
system. hTERT protein was detected by immunochemistry and flow cytometry. Cell viability was detected by
3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium (MTT) assay. Cell apoptosis was observed by morphological method
and determined by flow cytometry. Results: The telomerase activity decreased with time after hTERT AS PS-ODN
treatment. The levels of hTERT mRNA decreased with time after hTERT AS PS-ODN treatment, which appeared
before the decline of the telomerase activity. The percentage of positive cells of hTERT protein declined with time
after hTERT AS PS-ODN treatment, which appeared after the decline of hTERT mRNA. There was no difference in
telomerase activity, hTERT mRNA and protein levels between hTERT sense phosphorothioate oligodeoxynucleotide
(S PS-ODN) and the control group. The cell viability decreased with time after hTERT AS PS-ODN combined with
TNF-α treatment. The percentage of apoptosis increased with time after hTERT AS PS-ODN combined with
TNF-a treatment. There was no difference in cell viability and the percentage of apoptosis between hTERT S PS-ODN and
the control group. Conclusion: hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating
the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can
enhance TNF-α-induced apoptosis of PC3 cells. (Asian J Androl 2007 Sep; 9: 697_704)
Keywords: human telomerase reverse transcriptase; antisense phosphorothioate oligodeoxynucleotide; telomerase; prostate cancer cells;
tumor necrosis factor-α
Correspondence to: Dr Xiao-Dong Gao, Lanzhou University, 9 Qingyang Road, Zhaoyin Mansion, Chengguan District, Lanzhou 730000,
China.
Tel: +86_931-872-6767
Email: gxd58038@yahoo.com.cn
Received 2006-11-23 Accepted 2007-04-05
DOI: 10.1111/j.1745-7262.2007.00297.x
1 Introduction
In developed countries, prostate cancer is a main
cause of cancer-related deaths in men. Androgen
ablation is the main treatment for advanced prostate cancer.
This therapy is very effective in androgen-dependent
cancer; however, as a result of the emergence of
androgen-independent cells, tumors have become insensitive
to this kind of treatment, rendering anti-androgen therapy
ineffective [1]. Amplification of the androgen receptor
gene is the most common cause by which prostate tumors have become androgen independent. Approximately
30% of tumors exhibiting androgen independence after
ablation therapy show overexpression of the androgen
receptor [2]. Therefore, we should find new targets for
treatment of androgen-independent prostate cancer.
Telomeres are specialized heterochromatin structures
that protect the ends of chromosomes. Studies have
shown that telomerase activity is found in 85%_90% of
all human tumors, but not in their adjacent normal cells
[3]. This makes telomerase a good target not only for
cancer diagnosis, but also for the development of novel
therapeutic agents. Telomerase is composed of at least
three subunits: human telomerase RNA component (hTR),
human telomerase-associated protein (TEP1) and human
telomerase catalytic subunit (hTERT). The RNA subunit and the catalytic subunit are the essential
components for telomerase activity. The RNA subunit of
telomerase serves as the template for addition of short
sequence repeats to the chromosome 3' ends. The
catalytic subunit, telomerase reverse transcriptase, is the most
important component in telomerase complex, which is
responsible for catalytic activity of telomerase. The
expression of hTERT correlates with the presence of
telomerase activity [4].
The hTERT gene seems to be regulated by androgens
[5, 6]. Administration of androgens to androgen-sensitive
prostate cancer cells activates the hTERT promoter,
whereas androgen ablation leads to a decrease in hTERT
expression accompanied by a concomitant reduction in
telomerase activity which, in turn, is reversed by the
subsequent administration of androgens. Therefore, hTERT
is a good target for gene therapy to prostate cancer.
According to the initial paradigm for telomerase
inhibitors, telomerase inhibitors should initially decrease
telomerase activity without affecting the growth rate.
Decreased proliferation should only be observed when
the telomeres reach a critically short length. The lag
phase between the times at which telomeres shorten
sufficiently to produce detrimental effects on cancer cells is
a serious obstacle for the application of anti-telomerase
strategy, especially in cancer cells with long telomeres.
Moreover, lengthy exposure to anti-telomerase agents can
lead to the development of resistant tumor cells through
overexpression of telomerase activity or reactivation of
alternative telomere-lengthening mechanisms [1].Therefore, the combination of anti-telomerase strategy
with conventional drugs might improve the response of
prostate cancer. One way to overcome this limitation
might be to combine telomerase inhibition with
DNA-damaging chemotherapeutic drugs. There is a
possibility that inhibition of telomerase activity with hTERT
antisense might increase susceptibility of prostate cancer
cells (PC3) to immunotherapy drug-induced apoptosis.
In the present paper, an in vitro study was performed
to examine if inhibition of telomerase activity with hTERT
mRNA antisense can increase tumor necrosis
factor-α (TNF-α)-induced apoptosis of PC3 cells.
2 Materials and methods
2.1 Design and synthesis of antisense phosphorothioate
oligodeoxynucleotide (AS PS-ODN)
Oligodeoxynucleotide synthesis was designed as
described previously [7]. Based on the hTERT
gene cDNA sequence, from upstream 6-base and downstream
11-base at start code, 20-antisense oligomers were
synthesized, purified and modified by phosphorothioate
from Shanghai Institute of Biochemistry (Shanghai,
China). The AS PS-ODN sequence is
5'-GGAGCGCGCGGCATCGCGGG-3', which can recognize the catalytic subunit
template region of telomerase. The sense
phosphorothioate oligodeoxynucleotide (S PS-ODN) sequence is
5'-CCCGCGATGCCGCGCGCTCC-3', as a control. Through examination of the Blask soft from the Internet
(http: //www.ncbi.nlm.nih.gov/BLAST/), there is no
homologue for the antisense sequence with other genes
except hTERT cDNA.
2.2 Cell culture
Human prostate cancer cell lines were kindly
provided by the Research Institute of the Second Hospital,
Lanzhou University (Lanzhou, China). PC3 were
incubated in RPMI 1640 medium with 10% newborn bovine
serum containing 100 U/mL penicillin and 100 µg/mL
streptomycin at 37ºC under 5% CO2. The experiments
were divided into three groups: AS PS-ODN, S PS-ODN
and normal control group, each group consisting of three
wells on 24-well plates. Oligomers were added into the
wells with a concentration of 10 µmol/L. Cell telomerase
activity was measured 24, 48, 72 h later.
2.3 Detection of telomerase activity by the telomeric
repeat amplification protocol (TRAP) and telomerase
polymerase chain reaction enzyme-linked immunoassay
(PCR-ELISA)
Telomerase activity was detected using the TRAP
and the PCR-ELISA kit (Kaiji Bioengineering, Nanjing,
China). Briefly, the cell extract was prepared at
different time points of treatment. The negative control group
was established in each experiment. Cell extract was
heated to 65ºC for 10 min as a negative control.
2.3.1 Qualitative analysis by TRAP assay
For qualitative analysis by TRAP, 25 µL reaction
mixture was transferred into a tube suitable for PCR
amplication, and then 2 µL cell extract and sterile water
were added to the final volume of 50 µL. The PCR
condition was as follows: the telomerase reaction was
carried out at 25ºC for 30 min, followed by PCR
amplification of 30 cycles: at 94ºC for 30 s for denaturation, at
50ºC for 30 s for annealing of primers, at 72ºC for 90 s
for polymerization and at 72ºC for 10 min for balance.
The PCR products were revealed by 12% polyacrylamide no denaturing gel electrophoresis-silver staining.
2.3.2 Quantitative analysis by PCR-ELISA assay
For quantitative analysis by PCR-ELISA assay, 5 µL
amplified product and 20 µL denaturated reagent were
incubated at room temperature, and then 225 µL
hybridization buffer was added into the mixture. After 100 µL
mixture was distributed in the wells of a microtiter plate
at 37ºC for 2 h, 100 µL anti-DIG-POD (peroxidase)
working solution was added and incubated for 30 min.
Finally, 100 µL 3,3'-5,5'-tetramethyl benzidine substrate
solution was added and incubated for 10 min at room
temperature for color development, and then 100 µL stop
reagent was added to stop the reaction. Absorbance (A)
values were determined at 450_655 nm to calculate
A = A450_A655.
2.4 Analysis of human telomerase reverse transcriptase
(hTERT) mRNA by reverse transcription polymerase chain reaction (RT-PCR) assay
Total RNA was extracted from the AS PS-ODN, S PS-ODN or media-treated cells with the Trizol RNA kit
(Shenggong Bioengineering, Shanghai, China) and
RT-PCR reaction was performed with the One Tube
RT-PCR kit (Shenggong Bioengineering, Shanghai, China).
hTERT up-stream primer is 5'-CGGAAGAGTGTCTGGAGCAA-3' and hTERT down-stream primer is
5'-GGATGAAGCGGAGTCTGGA-3'. Beta-actin up-stream primer is 5'-GTGGGGCGCCC
CAGGCAGGCACCA-3' and β-actin down-stream primer is
5'-GTCCTTAATGTCACGCACGATTTC-3' (Shenggong Bioengineering, Shanghai, China). PCR consisted of one
cycle at 40ºC for 30 min, at 94ºC for 2 min, followed by
PCR amplification of 35 cycles: at 94ºC for 15 s for
denaturation, at 55ºC for 30 s for annealing of primers
and at 72ºC for 8 min for extension. PCR products were
assayed on a 2.0% agarose gel, visualized by ethidium
bromide staining and analyzed with gel-image system.
2.5 Determination of hTERT protein by flow cytometry
The levels of hTERT protein were determined using
an immunochemical assay kit (Zhongshan Golden Biotechnology, Beijing, China). Cells were collected and
fixed with 70% formaldehyde at 4ºC for 15 min. After
being washed with phosphate buffer solution (PBS) twice, the cells were incubated with 50 µL hTERT
protein antibody at 4ºC for 1 h, and then 50 µL FITC-IgG
of rabbit anti-goat was added and incubated at 4ºC for
30 min. Finally, the mixture was washed twice with the
PBS and hTERT protein was determined by flow cytometry.
2.6 Treatment of cells by AS PS-ODN combined with tumor
necrosis factor-α and detection of cell viability by 3-(4,
5-dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium (MTT) assay
The experiments were divided into six groups:
normal control, AS PS-ODN, S PS-ODN, TNF-α, TNF-α/AS
PS-ODN and TNF-α/S PS-ODN. Each group consisted of three repeat wells on 24-well plates. The AS
PS-ODN was added into the wells with a concentration
of 10 µmol/L. After the cells had been treated with AS
PS-ODN for 24 h, 4 µg/mL TNF-α was added into the
wells. The cell viability was detected by MTT assay
(Baiao Bioengineering, Beijing, China) at 24, 48, 72 and
96 h. Briefly, the MTT solution (5 g/L) was added to
each well and incubated at 37ºC for 4 h, and then culture
medium was removed and 100 µL dimethyl sulfoxide was
added to dissolve the formazan. Finally, the density of
each well was detected at 590 nm using a microplate
reader. The inhibition of cell viability was calculated using
the following formula: (1_average A value of
experimental group/average A value of control group) × 100%.
2.7 Observation of morphological feature of apoptosis
by inverted microscope
After the cells had been inhibited with 10 µmol/L AS
PS-ODN for 24 h, 4 µg/mL TNF-α was incubated with
PC3 cells for 48 h, and then the cells were observed
under the inverted microscope and photos were taken.
2.8 Determination of apoptotic cells by flow cytometry
Cells were collected by low centrifugation and washed with ice-cold PBS, and then recollected by
centrifugation. After being washed with the PBS twice,
the cells were incubated in 10 µL Annexin V-FITC
(fluorescein isothiocyanate) and 5 µL propidium iodine
at 4ºC for 30 min using the Annexin V-FITC apoptosis
assay kit (Baiao Bioengineering, Beijing, China). Finally,
the cells were analyzed within 60 min by flow cytometry.
2.9 Statistical analysis
Results were expressed as mean ± SD and
statistically compared using the Kruskal_Wallis H-test.
Statistical analyses were carried out with the software
package SPSS version 10.0 (SPSS Inc., Chicago, IL, USA).
The significance level was set at P < 0.05.
3 Results
3.1 Effect of AS PS-ODN on the telomerase activity of
prostate cancer cells
To evaluate the effect of AS PS-ODN on the telomerase activity of PC3 cells, the telomerase activity was
measured using the TRAP assay and the telomerase
PCR-ELISA assay. There was little effect of 10 µmol/L AS
PS-ODN on telomerase activity from 24 to 48 h; the
telomerase activity was significantly repressed after 48 h.
There was no effect of 10 µmol/L S PS-ODN on
telomerase activity of PC3 cells (P < 0.05; Figures 1 and
2). These findings suggest that this inhibitory action
was sequence specific in a time-dependent manner.
3.2 Effect of AS PS-ODN on the levels of hTERT mRNA
in prostate cancer cells
To clarify the relationship between telomerase
activity and hTERT mRNA, the levels of hTERT mRNA were
measured by RT-PCR and gel-image system. The levels
of hTERT mRNA were significantly decreased after PC3
cells had been treated with 10 µmol/L AS PS-ODN for
24 h, which occurred before the decline of the telomerase
activity. However, there was no effect of 10 µmol/L S
PS-ODN on the levels of hTERT mRNA in PC3 cells
(P < 0.05; Table 1,
Figure 3).
3.3 Effect of AS PS-ODN on the expression of human
hTERT protein in prostate cancer cells
To make further elucidate the relationship between
the hTERT mRNA and hTERT protein, the expression of
hTERT protein was determined by flow cytometry. The
percentage of positive cells of hTERT protein was
significantly declined compared to that of S PS-ODN after
PC3 cells had been treated with 10 µmol/L AS PS-ODN
for 48 h, which occurred after the decline of hTERT
mRNA (P < 0.05; Table 2).
3.4 Effect of AS PS-ODN on the cell viability of
prostate cancer cells
The inhibition of cell viability was detected by MTT
assay. The results showed that there was a significant
decrease in the cell viability of PC3 cells treated with
10 µmol/L AS PS-ODN combined with 4 µg/mL
TNF-α. There was no significant decrease in the cell viability of
PC3 cells treated with 10 µmol/L S PS-ODN combined
with 4 µg/mL TNF-α (P < 0.05; Figure 4).
3.5 Effect of AS PS-ODN on the morphological feature
of apoptosis in prostate cancer cells
The morphological features of apoptosis in PC3 cells
were observed under a microscope. Many apoptotic cells
were discovered after the cells had been treated with
10 µmol/L AS PS-ODN combined with 4 µg/mL
TNF-α for 48 h. No apoptotic features were observed in PC3
cells treated with 10 µmol/L S PS-ODN combined with
4 µg/mL TNF-α (Figure 5).
3.6 Effect of AS PS-ODN on the percentage of apoptosis
in prostate cancer cells
The percentage of apoptosis was determined by flow
cytometry. There was a significant increase in the
percentage of apoptosis in PC3 cells treated with 10 µmol/L
AS PS-ODN combined with 4 µg/mL TNF-α for 48 h,
but no significant increase in the percentage of apoptosis
in PC3 cells treated with 10 µmol/L S PS-ODN
combined with 4 µg/mL TNF-α, which indicates that this
apoptotic induction was sequence-specific in a
time-dependent manner (P < 0.05; Figures 6 and 7).
4 Discussion
Promising approaches that directly target either
telomerase or the telomerase-associated regulatory
mechanisms are reported in the present paper.
Strategies targeting telomerase-positive cells are means of
directly killing tumor cells [8]. Among three major
components of telomerase, hTERT, as the essential
component in telomerase complex, plays an important role in
telomerase activity. Recent studies demonstrate that
telomerase activity is significantly associated with hTERT
mRNA expression but not with hTR or TEP1 mRNA expression. These findings provide strong evidence that
the expression of hTERT is a rate-limiting determinant
of the enzymatic activity of human telomerase and that
the upregulation of hTERT expression might play a
critical role in human carcinogenesis [9]. Many studies
demonstrate that antisense oligonucleotides against human
telomerase RNA results in inhibition of telomerase
activity and induction of apoptosis in ovarian cancer cells and
prostate cancer cells [10].
In the present study, the data show that telomerase
activity was significantly downregulated or inhibited.
(Figures 1 and 2). The levels of hTERT mRNA decreased
significantly, which occurred before the decline of
telomerase activity (Table 1, Figure 3). The expression
of hTERT protein was declined significantly, occurring
after the decline of hTERT mRNA (Table 2). These
results suggest that AS PS-ODN regulated the telomerase
activity of PC3 cells by modifying the hTERT mRNA level
and hTERT protein, which consistent with similar research
from another laboratory [11]. In these experiments,
we did not find non-sequence-specific ribonucleic acid
enzyme H (RNaseH) inhibition of S PS-ODN [12]. Our
findings suggest that this inhibitory action was sequence
specific in a time-dependent manner.
TNF-α has shown cytotoxity in vitro. Different
tumor cells have different sensitivities for TNF-α-induced
apoptosis. Approximately 40% of tumor cells have growth
inhibition or cell lysis [13]. The results show that hTERT
AS PS-ODN combined with TNF-α could significantly decrease the cell viability of PC3 cells (Figure 4) and
increase the percentage of apoptosis in PC3 cells (Figures 5_7). hTERT S PS-ODN combined with
TNF-α could not induce apoptosis of PC3 cells, indicating
that this inhibitory and inducing action is sequence
specific in a time-dependent manner.
The mechanism of apoptosis of sensitive cells
induced by TNF-α is supported by the fact that
TNF-α can trigger the signal transduction and initiate apoptosis
after combining with the specific TNF-α receptor (TNFRI) in target cell membrane [14]. TNFRI is a death
receptor, which can activate the endogenous nuclease
(DNase) and caspase family by combining with TNF-α [15]. hTERT inhibition leads to a gradual reduction in
telomere length followed by growth arrest or apoptosis;
moreover, researchers have found that suppression of
hTERT expression abrogates the cellular response to DNA
double strand breaks. Loss of hTERT does not alter
short-term telomere integrity, but instead affects the
overall configuration of chromatin. Under the downregulation
of telomerase and the tumor cells lacking hTERT, the
tumor cells diminish capacity for DNA repair, fragment
chromosomes and impair the DNA damage response; cells lacking hTERT exhibit an increased susceptibility
to apoptosis-induced agents [16]. Hence, TNF-α can
easily divide DNA cells into fractions by the function of
endogenous nuclease. hTERT inhibition sensitizes PC3 cells
to TNF-α-induced apoptosis, which might improve
clinical cytokine therapy for prostate cancer.
Other studies show that overexpression of hTERT
protected a maturation-resistant acute promyelocytic
leukemia (APL) cell line from apoptosis induced by
TNF-α. The cells expressing high telomerase activity were more
resistant to apoptosis than those with low telomerase
expression [17]. Treatment with antisense telomerase
inhibited the telomerase activity and, subsequently,
induced either apoptosis or differentiation. The regulation
of these two distinct pathways might depend on the
expression of interleukin-1 β-converting enzyme or
cylin-dependent kinase inhibitors [18].
Results in these experiments are some similar to those
of Zhang et al. [19]. However, their experiments aim to
construct hTERT gene negative dominant mutation
vectors and to transfer them into tumor cells so that cell
telomerase activity is lowed or inhibited. It is easy to
consider problems regarding virus-vector safety. However, it is hard to eliminate the possibility of virus
vectors contaminating human genetic materials, which
could produce serious problems. Use of antisense
oligonucleotides to develop a new genetic drug might remove
this problem.
In conclusion, the present study shows, for the first
time, that hTERT inhibition sensitizes PC3 cells to
TNF-α-induced apoptosis. AS PS-ODN is a promising
treatment strategy for prostate cancer with telomerase activity.
Acknowledgment
This research was supported by grants from the key
foundation of Natural Science of Gansu Province. The
technical assistance of Mr Fu-Guo Wu is appreciated.
References
1 Biroccio A, Leonetti C. Telomerase as a new target for the
treatment of hormone-refractory prostate cancer. Endocr Relat
Cancer 2004; 11: 407_21.
2 Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E,
Isola J, et al. Androgen receptor gene amplification: a possible
molecular mechanism for androgen deprivation therapy failure
in prostate cancer. Cancer Res 1997; 7: 2071_9.
3 Kim NW. Clinical implications of telomerase in cancer. Eur J
Cancer 1997; 33: 781_6.
4 Yokoyama Y, Takahashi Y, Shinohara A, Wan X, Takahashi S,
Niwa K, et al. The 5'-end of hTERT mRNA is a good target for
hammerhead ribozyme to suppress telomerase activity.
Biochem Biophys Res Commun 2001; 61: 3053_61.
5 Guo C, Armbruster BN, Price DT, Counter CM.
In vivo regulation of hTERT expression and telomerase activity by
androgen. J Urol 2003; 170: 615_8.
6 Xu XF, Zhou SW, Zhang X, Ye ZQ, Zhang JH, Ma X,
et al. Prostate androgen-regulated gene: a novel potential target for
androgen-independent prostate cancer therapy. Asian J Androl
2006; 8: 455_62.
7 Blackburn EH. Switching and signaling at the telometer. Cell
2001; 106: 661_73.
8 Helder MN, Jong S, Vries EG, Zee AG. Telomerase targeting
in cancer treatment: new developments. Drug Resist Updat
1999; 2:104_15.
9 Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M.
Expression of human telomerase subunits and correlation with
telomerase activity in urothelial cancer. Clin Cancer Res 1998;
4: 1603_8.
10 Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted
therapy of human malignant glioma in a mouse model by 2-5A
antisense directed against telomerase RNA. Oncogene 1998;
16: 3323_30.
11 Nakayama J, Tahara H, Tahara E, Satio M, Ito K, Nakamura
H, et al. Telomerase activation by hTERT in human normal
fibroblasts and hepatocellular carcinomas. Nat Genet 1998;
18: 65_8.
12 Yu WQ, Sun B Z, Chen Z. Effect of antisense
oligodeoxynucleotide to PML-RARa fusion gene on acute promyelocytic
leukemia cell line NB4. Chin J Hematol 1998; 19: 227_30.
13 Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630_2.
14 Coffman FD, Haviland DL, Green LM, Ware CF. Cytotoxicity
by tumor necrosis factor is linked with the cell cycle but does
not require DNA synthesis. Growth Factor 1989; 1: 357_64.
15 Zhang QX, He LY, Li PF. Molecular Biology in Medicine.
Zhengzhou: Zhengzhou University Press; 2003.
16 Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z,
Manola JB, et al. The telomerase reverse transcriptase
regulates chromatin state and DNA damage responses. Proc Natl
Acad Sci U S A 2005; 102: 8222_7.
17 Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M,
Segal-Bendirdjian E. Death receptor signaling regulatory
function for telomerase: hTERT abolishes TRAIL-induced
apoptosis, independently of telomere maintenance. Oncogene
2004; 23: 7469_74.
18 Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka
Y, et al. Antisense telomerase treatment: induction two
distinct pathways, apoptosis and differentiation. FASEB J 1998;
12: 801_11.
19 Zhang X, Ma V, Zhou W, Harrington L, Robinson MO.
Telomere shortening and apoptosis in telomerase-inhibited
human tumor cells. Genes Dev 1999; 13: 2388_99.
|